Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells

Leukemia Research

Volumn 31, Issue 5, 2007, Pages 673-682

  Ikezoe, Takayuki ^a   Nishioka, Chie ^a   Bandobashi, Kentaro ^a   Yang, Yang ^a   Kuwayama, Yoshio ^a   Adachi, Yoshihiro ^a   Takeuchi, Tamotsu ^a   Koeffler, H Phillip ^b   Taguchi, Hirokuni ^a  

^a KOCHI UNIVERSITY   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

4E BP 1; Akt; ATL; mTOR; p70S6K; PI3K

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CYCLIN D1; EVEROLIMUS; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE; SERINE;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; IC 50; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; SIGNAL TRANSDUCTION; T CELL LEUKEMIA;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL CYCLE; CHROMONES; CYCLINS; ENZYME INHIBITORS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED; MORPHOLINES; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SIROLIMUS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 34147124095     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.08.001     Document Type: Article

References (29)

1. Hinuma Y., Nagata K., Hanaoka M., Nakai M., Matsumoto T., Kinoshita K.I., et al. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 78 (1981) 6476-6480
2. Yoshida M., Miyoshi I., and Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 79 (1982) 2031-2035
3. Taguchi H., Kinoshita K.I., Takatsuki K., Tomonaga M., Araki K., Arima N., et al. An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support. J Acquir Immune Defic Syndr Hum Retrovirol 12 (1996) 182-186
4. Yamada Y., Tomonaga M., Fukuda H., Hanada S., Utsunomiya A., Tara M., et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 113 (2001) 375-382
5. Franke T.F., Kaplan D.R., and Cantley L.C. PI3K: downstream AKTion blocks apoptosis. Cell 88 (1997) 435-437
6. Bjornsti M.A., and Houghton P.J. Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell 5 (2004) 519-523
7. Hay N., and Sonenberg N. Upstream and downstream of mTOR. Genes Dev 18 (2004) 1926-1945
8. Davies M.A., Kim S.J., Parikh N.U., Dong Z., Bucana C.D., and Gallick G.E. Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin Cancer Res 8 (2002) 1904-1914
9. Steck P.A., Pershouse M.A., Jasser S.A., Yung W.K., Lin H., Ligon A.H., et al. Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15 (1997) 356-362
10. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 (1997) 1943-1947
11. Wu X., Senechal K., Neshat M.S., Whang Y.E., and Sawyers C.L. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA 95 (1998) 15587-15591
12. Larizza L., Magnani I., and Beghini A. The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia. Leuk Lymphoma 4 (2005) 247-255
13. Cheng J.Q., Lindsley C.W., Cheng G.Z., Yang H., and Nicosia S.V. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 24 (2005) 7482-7492
14. Jimenez C., Jones D.R., Rodriguez-Viciana P., Gonzalez-Garcia A., Leonardo E., Wennstrom S., et al. Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase. EMBO J 17 (1998) 743-753
15. Ikezoe T., Yang Y., Saito T., Koeffler H.P., and Taguchi H. Proteasome inhibitor PS-341 down-regulates level of PSA and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells. Cancer Sci 95 (2004) 271-275
16. Ikezoe T., Yang Y., Bandobashi K., Saito T., Takemoto S., Machida H., et al. Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. Mol Cancer Ther 4 (2005) 578-586
17. Ikezoe T., Saito T., Bandobashi K., Yang Y., Koeffler H.P., and Taguchi H. HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2. Mol Cancer Ther 3 (2004) 473-479
18. Liu Y., Wang Y., Yamakuchi M., Masuda S., Tokioka T., Yamaoka S., et al. Phosphoinositide-3 kinase-PKB/Akt pathway activation is involved in fibroblast Rat-1 transformation by human T-cell leukemia virus type I tax. Oncogene 3 20 (2001) 2514-2526
19. Jeong S.J., Pise-Masison C.A., Radonovich M.F., Park H.U., and Brady J.N. Activated AKT regulates NF-kappaB activation, p53 inhibition and cell survival in HTLV-1-transformed cells. Oncogene 24 (2005) 6719-6728
20. Sanda T., Asamitsu K., Ogura H., Iida S., Utsunomiya A., Ueda R., et al. Induction of cell death in adult T-cell leukemia cells by a novel IkappaB kinase inhibitor. Leukemia 20 (2006) 590-598
21. Ma L., Chen Z., Erdjument-Bromage H., Tempst P., and Pandolfi P.P. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121 (2005) 179-193
22. Rolfe M., McLeod L.E., Pratt P.F., and Proud C.G. Activation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 (TSC2). Biochem J 388 (2005) 973-984
23. Recher C., Beyne-Rauzy O., Demur C., Chicanne G., Dos Santos C., Mas V.M., et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 105 (2005) 2527-2534
24. Xu Q., Simpson S.E., Scialla T.J., Bagg A., and Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 102 (2003) 972-980
25. Tabernero J., Rojo F., Burris H., Casado E., Macarulla T., Jones S., et al. A phase I study with tumor molecular pharmacodynamic evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients with advanced solid tumors. Proceedings of the ASCO annual meeting (2005) [Abstract #3007]
26. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66 (2006) 1500-1508
27. Breslin E.M., White P.C., Shore A.M., Clement M., and Brennan P. LY294002 and rapamycin co-operate to inhibit T-cell proliferation. Br J Pharmacol 144 (2005) 791-800
28. Sarbassov D.D., Ali S.M., Kim D.H., Guertin D.A., Latek R.R., Erdjument-Bromage H., et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14 (2004) 1296-1302
29. Sarbassov D.D., Guertin D.A., Ali S.M., and Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005) 1098-1101